Effect of 5‑aza‑2′‑deoxycytidine on Estrogen Receptor Alpha/Beta and DNA Methyltransferase 1 Genes Expression, Apoptosis Induction, and Cell Growth Prevention of the Colon Cancer HT 29 Cell Line

Masumeh Sanaei, Fraidoon Kavoosi

Abstract


Background: Cellular activity such as gene expression is regulated by epigenetic mechanisms and modifications. In mammals, DNA methylation is an essential component of the epigenetic machinery of the cells. DNA hypermethylation of the several tumor suppressor genes (TSGs) is associated with transcriptional gene silencing resulting in colon tumorigenesis. Overexpression of DNA methyltransferase 1 (DNMT1) in colon cancer has been reported in several studies. The methylation of estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) have been demonstrated in various cancers. Previously, we indicated that genistein can reactivate ERα in hepatocellular carcinoma (HCC). The present study was designed to investigate the effect of 5‑aza‑2′‑deoxycytidine (5‑aza‑CdR) on ERα/ERβ and DNMT1 gene expression, apoptosis induction, and cell viability inhibition of the colon carcinoma HT 29 cell line.

Methods: The effect of 5‑Aza‑CdR on the colon carcinoma HT 29 cell viability was measured by MTT assay. To determine the apoptotic cells, the cells were assessed using the Annexin V‑FITC/PI detection kit. The expression of ERα, ERβ, and DNMT1 genes was determined using real‑time quantitative RT‑PCR.

Results: The results indicated that 5‑Aza‑CdR can inhibit cell growth significantly versus control groups, induce significant apoptosis, down‑regulate DNMT1, and up‑regulate ERα and ERβ genes expression at different time periods. The percentage of apoptotic cells was 85.83% and 86.84% after 24 and 48 h, respectively (P < 0.01). The IC50 value for 5‑Aza‑CdR was obtained at 2.5 µM.

Conclusions: 5‑Aza‑CdR can up‑regulate ERα and ERβ genes expression through DNMT1 down‑regulation resulting in apoptosis induction and cell growth prevention.


Keywords


5‑aza‑2′‑deoxycytidine; colon cancer; epigenetic

Full Text:

PDF

References


VideticPaska A, Hudler P. Aberrant methylation patterns in

cancer: A clinical view. Biochem Med (Zagreb) 2015;25:161‑76.

Inbar‑Feigenberg M, Choufani S, Butcher DT, Roifman M,

Weksberg R. Basic concepts of epigenetics. Fertil Steril

;99:607‑15.

Mazzio EA, SolimanKF. Basic concepts of epigenetics: Impact

of environmental signals on gene expression. Epigenetics

;7:119‑30.

Kang C, Song J‑J, Lee J, Kim MY. Epigenetics: An emerging

player in gastric cancer. World J Gastroenterol 2014;20:6433.

Subramaniam D, Thombre R, Dhar A, Anant S. DNA

methyltransferases: A novel target for prevention and therapy.

FrontOncol 2014;4:80.

Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun H‑M,

Van Den Berg D, et al. Genome‑scale analysis of aberrant DNA

methylation in colorectal cancer. Genome Res 2012;22:271‑82.

Samaei NM, Yazdani Y, Alizadeh‑Navaei R, Azadeh H,

Farazmandfar T. Promoter methylation analysis of

WNT/β‑catenin pathway regulators and its association with

expression of DNMT1 enzyme in colorectal cancer. J BiomedSci

;21:73.

Pereira MA, Tao L, Wang W, Li Y, Umar A, Steele VE, et al.

Modulation by celecoxib and difluoromethylornithine of the

methylation of DNA and the estrogen receptor‑α gene in rat

colon tumors. Carcinogenesis 2004;25:1917‑23.

Mokarram P, Sheikhi M, Mortazavi S, Saeb S, Shokrpour N.

Effect of exposure to 900 MHz GSM mobile phone

radiofrequency radiation on estrogen receptor methylation status

in colon cells of male spraguedawley rats. J Biomed PhysEng

;7:79.

Caiazza F, Ryan EJ, Doherty G, Winter DC, Sheahan K. Estrogen

receptors and their implications in colorectal carcinogenesis.

FrontOncol 2015;5:19.

Sasaki M, Tanaka Y, Perinchery G, Dharia A, Kotcherguina I,

Fujimoto Si, et al. Methylation and inactivation of estrogen,

progesterone, and androgen receptors in prostate cancer. JNatl

Cancer Inst 2002;94:384‑90.

Lau K‑M, LaSpina M, Long J, Ho S‑M. Expression of estrogen

receptor (ER)‑α and ER‑β in normal and malignant prostatic

epithelial cells: Regulation by methylation and involvement in

growth regulation. Cancer Res 2000;60:3175‑82.

Wei M, Xu J, Dignam J, Nanda R, Sveen L, Fackenthal J, et al.

Estrogen receptor α, BRCA1, and FANCF promoter methylation

occur in distinct subsets of sporadic breast cancers. Breast

Cancer Res Treat 2008;111:113‑20.

Xue Q, Lin Z, Cheng Y‑H, Huang C‑C, Marsh E, Yin P, et al.

Promoter methylation regulates estrogen receptor 2 in human

endometrium and endometriosis. BiolReprod 2007;77:681‑7.

Mossman D, Kim KT, Scott RJ. Demethylation by

‑aza‑2’‑deoxycytidine in colorectal cancer cells targets genomic

DNA whilst promoter CpG island methylation persists. BMC

Cancer 2010;10:366.

Szyf M. The role of DNA hypermethylation and demethylation

in cancer and cancer therapy. CurrOncol 2008;15:72.

Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG,

Davidson NE. Synergistic activation of functional estrogen

receptor (ER)‑α by DNA methyltransferase and histone

deacetylase inhibition in human ER‑α‑negative breast cancer

cells. Cancer Res 2001;61:7025‑9.

Sanaei M, Kavoosi F, Salehi H. Genistein and trichostatin A

induction of estrogen receptor alpha gene expression, apoptosis

and cell growth inhibition in hepatocellular carcinoma HepG

cells. Asian Pac J Cancer Prev 2017;18:3445.

Latil A, Bièche I, Vidaud D, Lidereau R, Berthon P, Cussenot O,

et al. Evaluation of androgen, estrogen (ERα and ERβ), and

progesterone receptor expression in human prostate cancer by

real‑time quantitative reverse transcription‑polymerase chain

reaction assays. Cancer Res 2001;61:1919‑26.

Oya M, Schulz W. Decreased expression of p57 KIP2 mRNA in

human bladder cancer. Br J Cancer 2000;83:626.

Baylin S, Bestor TH. Altered methylation patterns in cancer cell

genomes: Cause or consequence? Cancer Cell 2002;1:299‑305.

Schnekenburger M, Diederich M. Epigenetics offer new horizons

for colorectal cancer prevention. Curr Colorectal Cancer Rep

;8:66‑81.

Marino M, Caiazza F. Estrogen signal transduction pathways

from plasma membrane to the nucleus. Signal Transduction

Research Trends. New York, NY: Nova Science Publisher; 2007.

p. 17‑44.

Kondo Y, Issa JP. Epigenetic changes in colorectal cancer.

Cancer Metastasis Rev 2004;23:29‑39.

Elbanna HG, Ebrahim MA, Abbas AM, Zalata K, Hashim MA.

Potential value of estrogen receptor beta expression in colorectal

carcinoma: Interaction with apoptotic index. JGastrointest Cancer

;43:56‑62.

Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW.

Selective loss of estrogen receptor β in malignant human colon.

Cancer Res 2000;60:245‑8.

Xiong H, Qiu H, Zhuang L, Xiong H, Jiang R, Chen Y.

Effects of 5‑Aza‑CdR on the proliferation of human breast

cancer cell line MCF‑7 and on the expression of Apaf‑1 gene.

J HuazhongUnivSciTechnolog Med Sci 2009;29:498‑502.

Yap OWS, Bhat G, Liu L, Tollefsbol TO. Epigenetic modifications of the estrogen receptor β gene in epithelial

ovarian cancer cells. Anticancer Res 2009;29:139‑44.

Hishida M, Nomoto S, Inokawa Y, Hayashi M, Kanda M,

Okamura Y, et al. Estrogen receptor 1 gene as a tumor suppressor

gene in hepatocellular carcinoma detected by triple‑combination

array analysis. Int JOncol 2013;43:88‑94.

Zhu X, Leav I, Leung Y‑K, Wu M, Liu Q, Gao Y, et al.

Dynamic regulation of estrogen receptor‑β expression by DNA

methylation during prostate cancer development and metastasis.

Am J Pathol 2004;164:2003‑12.

Yu J, Ma X, Cheung K, Li X, Tian L, Wang S, et al. Epigenetic

inactivation of T‑box transcription factor 5, a novel tumor

suppressor gene, is associated with colon cancer. Oncogene

;29:6464